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Deletions at 22q11.2 are linked to DiGeorge or velocardiofacial
syndrome (VCFS), whose hallmarks include heart, limb, and cranio-
facial anomalies, as well as learning disabilities and increased
incidence of schizophrenia. To assess the potential contribution of
22q11 genes to cognitive and psychiatric phenotypes, we deter-
mined the CNS expression of 32 mouse orthologs of 22q11 genes,
primarily in the 1.5-Mb minimal critical region consistently deleted
in VCFS. None are uniquely expressed in the developing or adult
mouse brain. Instead, 27 are localized in the embryonic forebrain
as well as aortic arches, branchial arches, and limb buds. Each
continues to be expressed at apparently constant levels in the fetal,
postnatal, and adult brain, except for Tbx1, ProDH2, and T10, which
increase in adolescence and decline in maturity. At least six 22q11
proteins are seen primarily in subsets of neurons, including some
in forebrain regions thought to be altered in schizophrenia. Thus,
22q11 deletion may disrupt expression of multiple genes during
development and maturation of neurons and circuits compromised
by cognitive and psychiatric disorders associated with VCFS.
There is a high incidence of schizophrenia in patients withvelocardiofacial syndrome (VCFS), which is caused by het-
erozygous deletion at chromosome 22q11 (1). In addition, these
patients have reduced cortical gray matter (2) similar to schizo-
phrenics. It is unknown whether specific 22q11.2 genes (3, 4)
mediate the neurocognitive and neuropathological aspects of
VCFS. Analysis of the VCFS cardiovascular phenotype was
facilitated by embryonic expression studies that suggested Tbx1
as a candidate (5, 6), a possibility that was subsequently verified
genetically in mice (7, 8). Accordingly, analysis of 22q11 gene
expression in the CNS might identify candidate genes that may
compromise brain development or function.
Currently, there is very little data on 22q11 gene expression in
the brain beyond COMT, a catecholamine catabolic enzyme
independently associated with schizophrenia (9). Although
COMT remains an attractive candidate, additional 22q11 genes
could influence neural development or function and thus con-
tribute to psychiatric aspects of VCFS. 22q11 genes might
influence forebrain as well as heart, face, and limb development
through participation in a shared developmental mechanism
[nonaxial mesenchymalepithelial (ME) induction (10, 11)]
that guides morphogenesis at each location. Furthermore, 22q11
genes might modulate later events in neural development
thought to be compromised in schizophrenia, including neuro-
genesis, migration, process outgrowth, and synapse formation
(12, 13).
To establish which 22q11 genes are the strongest candidates
for the effects of VCFS on brain development or function, we
undertook a comprehensive expression profile of 22q11 or-
thologs in the mouse, complemented by a selective analysis in the
human. We focused on orthologs of genes in the proximal 1.5
megabase (Mb) portion of the 3-Mb typically deleted region
because this 1.5-Mb portion includes the previously defined
‘‘minimal DiGeorge critical region’’ (14) thought to be crucial
for VCFS phenotypes. Our results do not suggest a limited
number of candidates; instead, a large subset of 22q11 genes, if
dysregulated by heterozygous deletion, might compromise de-
velopmental mechanisms or vulnerable neuronal populations
and thereby contribute to behavioral disorders in VCFS.
Methods
Genomic Analysis and Mapping. We confirmed and augmented
previous maps of proximal 22q11.2 and the syntenic region of
mouse chromosome 16 (8, 15, 16). We validated the GenBank-
derived cDNA sequence for each human 22q11 gene (17) against
the human EST cDNA database, as well as genomic sequences,
to identify exons and map orthologous genes. In addition, we
used genomic sequences to search mouse and human EST cDNA
databases for previously unidentified transcripts.
PCR Analysis. PCR primers for 22q11 genes and orthologs (Table
1, which is published as supporting information on the PNAS
web site) were optimized for a standardized PCR condition
(60°C annealing temperature, 50-sec extension time). Primers
span introns where possible and yield amplicons of 500 bp with
modest GC content (50–60%). Amplicons were verified by
sequencing.
Semiquantitative RT-PCR Analysis. We used outbred mice (ICR,
Harlan Breeders, Indianapolis) that are free of developmental or
brain anomalies common among inbred strains. Tissues were
dissociated in TRIzol (Invitrogen), DNase-treated to remove
residual genomic DNA (DNAfree, Ambion, Austin, TX), and
reverse transcribed (ImPromptII, Promega) by using random
hexamer primers (Invitrogen). Control reactions used an equal
amount of RNA without reverse transcriptase (RT) enzyme.
cDNA samples were standardized by competitive PCR (18), and
equivalent dilutions of each cDNA sample were established that
amplify -actin to similar levels. Each PCR analysis was repeated
two to five times from independent tissue samples, with equiv-
alent results. Two genes (GPIBB and GSCL) not represented in
these cDNAs were validated with EST or bacterial artificial
chromosome DNA samples. Human cDNAs were obtained from
BD Biosciences Clontech. Adult brain cDNAs reflect RNA
pooled from donors between 12 and 75 years of age; fetal cDNAs
were prepared from the pooled RNA of 12 fetuses aged 19–23
weeks.
Cellular Expression of Selected 22q11 Orthologs. Monoclonal anti-
bodies (COMT, RanBP1, and Ufd1L, Transduction Laborato-
ries, Lexington, KY) and goat polyclonal antiserum (CDC45L,
Santa Cruz Biotechnology) were obtained commercially. Rabbit
antisera against murine HIRA and CDCrel-1 were obtained by
immunization with a 15 C-terminal amino acid synthetic peptide
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(Washington Biotechnology, Baltimore) and affinity-purified
with the immunizing peptide. All antibodies were tested for
specificity by Western blot; rabbit antisera were also tested by
peptide preabsorption (data not shown). Immunolocalization
was performed on mouse embryos or brain sections as described
(19). All animals were handled in accordance with protocols
approved by the University of North Carolina Institutional
Animal Care and Use Committee.
Results
We identified, mapped, and verified sequences of 32 mouse
orthologs of 22q11 genes, including 25 in the proximal 1.5-Mb
portion consistently deleted in VCFS (Fig. 1a), to assemble a
comprehensive PCR-based expression array (Table 1). We
considered the membrane-bound isoform of COMT to be a
separate transcriptional unit because its transcription start site
and first exon are distinct. Primers for each remaining gene
detect sequences predicted to be common to all isoforms. We
identified two genes not included in previous maps, the
receptor for the NoGo protein (20) and zDHHC8, a 3-kb
transcript containing a DHHC-zinc finger domain. Five addi-
tional genes (DGCR6, ProDH2, BCR, E2F6, and GGT) are
found within the human LCRs (15) that are thought to mediate
both the typical 3-Mb deletion and the smaller 1.5-Mb dele-
tion. Evaluation of human genes in the LCRs is complicated
by the presence of multiple copies; however, we identified a
single copy of each in the mouse. Two genes (CRKL and
PCQAP) in the distal portion of the region typically deleted in
Fig. 1. (a) The top shows a scale map of the proximal 1.5-Mb portion of chromosome 22q11 consistently deleted in DiGeorge syndrome (containing 27 of 32
transcripts examined) showing transcription units (orange bars) and low-copy repeats (LCRs, white boxes). The bottom shows that a majority of mouse orthologs
are in a segment of mouse chromosome 16. (b) PCR array of 22q11.2 orthologs at sites of nonaxial ME interaction: the frontonasal massforebrain (FNMFB),
branchial arches (BA), aortic arches and heart (AAH), and forelimb buds (FLB). Expression is presented in chromosomal order, centromeric (top) to telomeric
(bottom). Brackets and arrows represent genes that share bidirectional promoters. The LCR bracket indicates genes found in human LCRs (not on chromosome
16 in mouse). -actin and GAPDH are positive controls. (c–h). Whole embryonic day (E) 10E10.5 mouse embryo immunolocalization of five 22q11 proteins shows
correspondence between message and protein localization for this subset of orthologs. (i–n) Whole E10E10.5 mouse embryo in situ hybridization of seven 22q11
orthologs shows focal expression at nonaxial inductive sites.
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VCFS were analyzed, because previous work suggests that they
are VCFS candidates (21, 22).
22q11 Genes at Sites of ME Interaction. We first asked whether
22q11 orthologs are expressed in the developing forebrain as well
as the heart, face, and limbs at midgestation [embryonic day (E)
10.5] when ME interactions influence patterning and morpho-
genesis at each site (23). Previous observations indicate that at
least nine murine orthologs (CDC45L, CDCrel-1, CRKL,
DGCR2, DGCR8, Hira, NLVCF, RanBP1, and Ufd1L) are
expressed at these sites (17). We confirmed these and evaluated
the remaining 23 genes in cDNAs from microdissected FNM
FB, first and second BA, AAH, and FLB (Fig. 1b) from E10.5
mouse embryos. The identity of each cDNA sample was vali-
dated by four differentially expressed genes: Pax7 (FNMFB),
Lhx 7 (BA), Tbx5 (BA and AAH), and HoxA13 (FLB). 27 of 32
murine 22q11 orthologs are expressed at all four sites at E10.5
(Fig. 1b). Although our PCR analysis is not intended to be
quantitative, we note that most transcripts are detected at
comparatively high levels at all four sites except Tbx1, which, as
reported in ref. 6, is enhanced in the heart and branchial arches,
and NoGoR, which is enhanced in the FLB.
To evaluate whether expression is limited to inductive sites, we
localized a subset of orthologs in whole mouse embryos by using
antibody or nucleic acid probes. We localized five proteins
[COMT, Ufd1l, CDCRel-1, RanBP1, and HIRA (Fig. 1 c–g)] by
using specific antibodies that recognize bands of appropriate
molecular weight by Western blot. We also selected six genes that
had not been previously localized for in situ analysis at E10.5–
E11: ARCVF, DGCR8, E2F6, Htf9C, WDVCF, and zDHHC8
(Fig. 1 i–n). Each was expressed in the FNMFB, BA, AAH, and
FLB. CDCrel-1, COMT, E2F6, HIRA, RanBP1, Ufd1l, and
zDHHC8 are primarily limited to the four nonaxial sites, whereas
Htf9C, ARVCF, WDVCF, and DGCR8 are also seen in ventral
midline structures.
22q11 Orthologs Are Expressed in Fetal and Adolescent Brain. We
next asked whether 22q11 orthologs continue to be expressed
during brain development. Of 27 genes expressed in the fore-
brain and other sites of ME interaction, 24 remain in the fetal,
postnatal, and adult brain (Fig. 2a). In the fetal brain, the protein
products of at least three genes are localized in zones where
proliferating, migrating, or differentiating neurons are found in
the developing neocortex. RanBP1 is seen in the ventricular zone
(Fig. 2b), where proliferating precursors are found, and in the
intermediate zone, where migrating neuroblasts are concen-
trated. Ufd1L is restricted to the intermediate zone (Fig. 2c).
COMT is mostly confined to the marginal zone and cortical plate
coincident with postmitotic, postmigratory neurons (Fig. 2d). In
the fetal and postnatal brain, three other orthologs found at
inductive sites (Tbx1, ProDH2, and T10) appear to be temporally
modulated. They are not readily detectable at E12, but are
robustly expressed at postnatal day (P) 25 (Fig. 2a). This is most
apparent for Tbx1, which is not detected until P7, increases at
Fig. 2. (a) PCR array showing expression of 22q11 orthologs in whole E10 and E14 mouse embryos and in the brain (anterior from the medulla) from E12 through
adulthood. A no-RT lane is included as a negative control for sample contamination, and -actin and GAPDH were used as positive controls. (b–d)
Immunolocalization (green) of three 22q11 proteins in the developing neocortex at E16 shows expression in distinct domains of the developing cortex
(cytoarchitecture shown with blue nuclear counterstain). vz, ventricular zone; iz, intermediate zone; cp, cortical plate. (e–h) Immunolocalization (green) of four
22q11 proteins in the adult neocortex suggests subtle variations in laminar frequency of labeled cells. Layer identity, demonstrated by blue nuclear counterstain,
is shown at left.








P25, and returns to barely detectable levels in the adult brain.
These changes coincide with that of Synaptophysin (SynPhy)
(24), a protein associated with synapse formation and stabiliza-
tion, and GAP43 (25), a protein associated with axon outgrowth
(Fig. 2a). The five remaining transcripts were not found in the
brain at any age, although three (GGT , Stk22a, and Stk22b) are
found in other adult tissues (see below).
22q11 Gene Expression in the Adult Brain. We next asked whether
22q11 gene expression varies in distinct brain regions. Twenty-seven
genes are expressed in the adult brain; however, ProDH2, TMVCF,
WDVCF, T10, and Tbx1 are more difficult to detect. Nevertheless,
all 27 are expressed in all major forebrain subdivisions: the neo-
cortex, hippocampus, basal ganglia, amygdalabasal forebrain, and
olfactory bulb, as well as all other CNS regions (Fig. 3a). No
ortholog is limited to the brain; most are expressed in other adult
tissues (Fig. 3b). Only three genes are restricted: the metabolic
enzyme GGT in kidney, and two small putative serine kinases
(Stk22a and Stk22b) primarily in testes. Thus, no 22q11 orthologs
are uniquely expressed in the developing or mature CNS, nor are
any orthologs limited to specific CNS regions.
To begin to distinguish whether 22q11 proteins are expressed
in neurons or in nonneural cells, we immunolocalized CDCrel-1,
CDC45L, COMT, HIRA, RanBP1, and Ufd1L in the mature
brain (Fig. 4). This subset represents a broad range of functional
classes and is widely distributed in the proximal 1.5-Mb portion
(17). All are expressed primarily in neurons; we saw no labeling
in astroglia or oligodendroglia (data not shown). CDCrel-1,
CDC45L, COMT, and Ufd1l are expressed by subsets of neurons
in multiple neocortical layers (Fig. 2c). There is no laminar
specificity; however, the frequency of CDCrel-1-labeled cells is
apparently reduced in layers 2 and 3, and that for CDC45L is
diminished in layer 4. RanBP1 and HIRA are expressed lightly
throughout the cortex; however, labeled cells are more frequent
in layer 6 for both (data not shown). All six proteins are also
expressed in subsets of basal ganglia neurons, with no apparent
specificity for any striatal compartment or cell class. In contrast,
hippocampal expression is not uniform: Ufd1L is primarily
found in CA2 and 3, COMT and HIRA are found in CA4 and
the dentate gyrus, and RanBP1 is found in small clusters in the
hilus of the dentate gyrus (Fig. 4). In contrast, CDCrel-1 and
CDC45L are found in pyramidal cells throughout all hippocam-
pal fields. There is also neuronal expression in the olfactory bulb,
thalamus, and cerebellum (data not shown and Fig. 4). A
substantial number of neurons in the neocortex, basal ganglia,
and hippocampus express more than one 22q11 protein (Fig. 6,
which is published as supporting information on the PNAS web
site); however, 22q11 protein-expressing neuronal populations
do not overlap completely. 22q11 proteins coincide in neurons in
other brain regions, including the cerebellum, where CDCrel-1,
HIRA, and Ufd1L are expressed in calbindin-positive Purkinje
cells (Fig. 4, bottom row). We cannot rule out the possibility that
other 22q11 proteins are expressed primarily in glial or cerebral
vascular cells; nevertheless, there is significant neuronal-
restricted expression of at least these six proteins throughout the
brain, including in regions potentially compromised in behav-
ioral and psychiatric disorders associated with VCFS.
Murine Analysis Predicts Human 22q11 Gene Expression. To deter-
mine whether essential aspects of the mouse expression profile
are retained in humans, we analyzed a subset of nine human
22q11 genes in cDNAs from fetal and adult human tissues. We
selected five genes (CDCrel-1, COMT, HIRA, RanBP1, and
Ufd1L) whose murine orthologs are expressed robustly at in-
ductive sites and continue to be expressed throughout develop-
ment, and whose protein products can be localized to subsets of
forebrain neurons. Our limited analysis of human expression
suggests that these genes are expressed widely in human tissues
(Fig. 5), as they are in mouse. Two additional genes (Tbx1 and
Stk22b, whose murine orthologs have restricted expression) are
similarly restricted in human tissues. The two transcripts not
previously analyzed in either mouse or human (zDHHC8 and
NogoR) are detected in human tissues including the brain.
Finally, in mouse, Znf74 does not encode a functional transcript
(16); however, it is expressed in the developing and mature
human brain and in nonneural tissues.
Discussion
Our expression analysis of a comprehensive set of 22q11 or-
thologs in the developing and adult mouse as well as a limited set
of 22q11 genes in the human does not suggest a single or small
number of candidate genes for schizophrenia or other cognitive
disorders associated with VCFS. Instead, most 22q11 genes are
expressed in the brain from early development through maturity.
Accordingly, increased vulnerability to schizophrenia in VCFS
may reflect consequences of heterozygous deletion of multiple
22q11 genes, some of which have distinct functions during
specific developmental epochs or in specific neuronal classes in
the mature brain.
27 of 32 orthologs are expressed in the forebrain during its
initial patterning, as well as at other sites phenotypically com-
promised by 22q11.2 deletion: the limb buds, aortic arches, and
branchial arches. A common cellular mechanism, ME induc-
tion, guides morphogenesis of these sites (23, 26–28). Disruption
of at least two inductive signals (retinoic acid and FGF8)
phenocopies aspects of VCFS (11, 29–31). Moreover, FGF8 and
another inductive signal, sonic hedgehog, modulate expression
of at least one 22q11 ortholog, Tbx1 (32), and heterozygous
deletion of FGF8 enhances penetrance of cardiovascular phe-
Fig. 3. (a) PCR array of microdissected adult forebrain regions and other CNS
domains shows expression of the 22q11 orthologs. (b) A PCR array of several
organs shows widespread expression of most 22q11 orthologs outside
the CNS.
14436  www.pnas.orgcgidoi10.1073pnas.2235651100 Maynard et al.
notypes when Tbx1 is deleted homozygously (33). Our results
suggest that additional 22q11 genes may be involved in ME
induction. Thus, in addition to anomalies of the limbs, heart, and
face, VCFS may subtly alter initial regional development and
subsequent cell and circuit differentiation in the forebrain.
Expression of most 22q11 orthologs continues in the fetal and
adolescent brain, throughout the critical processes of neuronal
proliferation, migration, and circuit differentiation. The local-
ization of COMT, Ufd1L, and RanBP1 in proliferating, migrat-
ing, or early postmigratory cortical cells, as well as the persistent
expression of at least 21 other orthologs in the fetal brain,
suggests that multiple 22q11.2 genes influence neurogenesis and
migration. In contrast, ProDH2, Tbx1, and T10 transcripts are
expressed in the adolescent mouse brain: after most migration as
well as axonal and dendritic growth, but during the refinement
and stabilization of synaptic connections (34). This synaptic
refinement is likely compromised in schizophrenics, based on
studies of histopathology and altered gene expression in post-
mortem brain tissue (13, 35). Thus, heterozygous deletion of
22q11 may alter the expression of genes required for proper
development and function of neuronal circuits in the CNS.
Schizophrenia is generally thought to be a multigenic dis-
ease with a distinct natural history that encompasses disrupted
neural development, maturation, and function (36). Thus, it is
not unexpected that our data enlarges, rather than limits, the
list of potential contributors associated with the high incidence
of schizophrenia in 22q11.2-deleted VCFS patients (1). Sev-
eral 22q11 genes have been linked to schizophrenia indepen-
dently of VCFS, including COMT (9), ProDH2 (37), Ufd1L
(38), and PCQAP (22). Our data strengthen the case that each
may contribute independently to altered brain function in
VCFS. Furthermore, several genes implicated in developmen-
tal or behavioral deficits associated with 22q11 deletion, based
on loss of function in mice, are expressed in brain regions
where local disruption of gene function might compromise
differentiation or maintenance of relevant brain circuits. Ab-
normal sensorimotor gating in COMT (39) or ProDH2 (40) null
mice, and similar deficiencies in heterozygous deletions of
large regions of mouse chromosome 16 (41), may ref lect direct
alteration of developing or mature neural circuits, rather than
some general systemic or metabolic effect. Homozygous de-
letion of several other orthologs, including CDC45L, CRKL,
Hira, Ufd1L, and Tbx1, is either lethal at early stages or results
in morphogenetic defects (17). Further analysis (e.g., using
conditional inactivation to circumvent early lethality) will be
Fig. 4. Immunolocalization (green) of six 22q11 proteins in the adult mouse brain shows expression in subsets of neurons in the striatum, hippocampus, and
cerebellum; a blue nuclear counterstain indicates the position of cell bodies. Double labeling with glial (second row, red) or neuronal (third row, red) markers
suggests that the cells expressing these 22q11 proteins are neurons.
Fig. 5. PCR expression array of selected human 22q11 genes. Human cDNA
pools were obtained from BD Biosciences Clontech. cDNAs from whole brain
and organ tissues were evaluated, and samples of forebrain and other CNS
regions are included at the far right.








necessary to better understand the contribution of these genes
to behavioral pathology associated with VCFS.
Our comprehensive expression analysis reinforces a conclu-
sion suggested by multiple genetic linkages within 22q11.2:
that the increased risk for schizophrenia associated with VCFS
ref lects the concerted action of multiple 22q11 genes. Given
the regional, temporal, and cellular coincidence shown here,
there may also be interactions between multiple 22q11 genes
in the CNS. The deletion of 22q11.2 genes as a group (as
commonly occurs in VCFS) may synergistically disrupt pro-
cesses required for proper brain development or function,
leading to a greatly increased risk for schizophrenia.
Note Added in Proof. A brief description of zDHHC8 was included
(as KIAA1292) in Liu et al. (42).
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